Michele T Yip-Schneider1, Mazhar Soufi2, Rosalie A Carr2, Katelyn F Flick2, Huangbing Wu2, Cameron L Colgate3, C Max Schmidt4. 1. Departments of Surgery, USA; Departments of Walther Oncology Center, USA; Departments of Indiana University Simon Cancer Center, USA; Departments of Indiana University Health Pancreatic Cyst and Cancer Early Detection Center, Indianapolis, IN, USA. 2. Departments of Surgery, USA; Departments of Indiana University Health Pancreatic Cyst and Cancer Early Detection Center, Indianapolis, IN, USA. 3. Departments of Center for Outcomes Research in Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. 4. Departments of Surgery, USA; Departments of Biochemistry/Molecular Biology, USA; Departments of Walther Oncology Center, USA; Departments of Indiana University Simon Cancer Center, USA; Departments of Indiana University Health Pancreatic Cyst and Cancer Early Detection Center, Indianapolis, IN, USA. Electronic address: maxschmi@iupui.edu.
Abstract
BACKGROUND: Intraductal papillary mucinous neoplasms (IPMN) are precursors of pancreatic cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC). Here, we seek to assess their ability to detect high-risk IPMN. METHODS: Urine was collected from patients undergoing pancreatic resection and healthy controls. TIMP-1(Tissue Inhibitor of Metalloproteinase-1), LYVE-1(Lymphatic Vessel Endothelial Receptor 1), and PGEM(Prostaglandin E Metabolite) levels were determined by ELISA and analyzed by Kruskal-Wallis. RESULTS: Median urinary TIMP-1 levels were significantly lower in healthy controls (n = 9; 0.32 ng/mg creatinine) compared to PDAC (n = 13; 1.95) but not significantly different between low/moderate-grade (n = 20; 0.71) and high-grade/invasive IPMN (n = 20; 1.12). No significant difference in urinary LYVE-1 was detected between IPMN low/moderate (n = 16; 0.37 ng/mg creatinine) and high/invasive grades (n = 21; 0.09). Urinary PGEM levels were not significantly different between groups. CONCLUSIONS: Urinary TIMP-1, LYVE-1, and PGEM do not correlate with malignant potential of pancreatic cysts.
BACKGROUND: Intraductal papillary mucinous neoplasms (IPMN) are precursors of pancreatic cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC). Here, we seek to assess their ability to detect high-risk IPMN. METHODS: Urine was collected from patients undergoing pancreatic resection and healthy controls. TIMP-1(Tissue Inhibitor of Metalloproteinase-1), LYVE-1(Lymphatic Vessel Endothelial Receptor 1), and PGEM(Prostaglandin E Metabolite) levels were determined by ELISA and analyzed by Kruskal-Wallis. RESULTS: Median urinary TIMP-1 levels were significantly lower in healthy controls (n = 9; 0.32 ng/mg creatinine) compared to PDAC (n = 13; 1.95) but not significantly different between low/moderate-grade (n = 20; 0.71) and high-grade/invasive IPMN (n = 20; 1.12). No significant difference in urinary LYVE-1 was detected between IPMN low/moderate (n = 16; 0.37 ng/mg creatinine) and high/invasive grades (n = 21; 0.09). Urinary PGEM levels were not significantly different between groups. CONCLUSIONS: Urinary TIMP-1, LYVE-1, and PGEM do not correlate with malignant potential of pancreatic cysts.
Authors: M T Yip-Schneider; D S Barnard; S D Billings; L Cheng; D K Heilman; A Lin; S J Marshall; P L Crowell; M S Marshall; C J Sweeney Journal: Carcinogenesis Date: 2000-02 Impact factor: 4.944
Authors: Ajay V Maker; Silvia Carrara; Nigel B Jamieson; Mario Pelaez-Luna; Anne Marie Lennon; Marco Dal Molin; Aldo Scarpa; Luca Frulloni; William R Brugge Journal: J Am Coll Surg Date: 2014-11-06 Impact factor: 6.113
Authors: Tomasz P Radon; Nathalie J Massat; Richard Jones; Wasfi Alrawashdeh; Laurent Dumartin; Darren Ennis; Stephen W Duffy; Hemant M Kocher; Stephen P Pereira; Luisa Guarner posthumous; Cristiane Murta-Nascimento; Francisco X Real; Núria Malats; John Neoptolemos; Eithne Costello; William Greenhalf; Nick R Lemoine; Tatjana Crnogorac-Jurcevic Journal: Clin Cancer Res Date: 2015-08-01 Impact factor: 12.531
Authors: Silvana Debernardi; Harrison O'Brien; Asma S Algahmdi; Nuria Malats; Grant D Stewart; Marija Plješa-Ercegovac; Eithne Costello; William Greenhalf; Amina Saad; Rhiannon Roberts; Alexander Ney; Stephen P Pereira; Hemant M Kocher; Stephen Duffy; Oleg Blyuss; Tatjana Crnogorac-Jurcevic Journal: PLoS Med Date: 2020-12-10 Impact factor: 11.069